Treats onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). ANDA 78163, held by Orbion Pharmaceuticals. Terbinafine Hydrochloride.
As of Nov 22, 2026, ANDA 78163 (Terbinafine Hydrochloride), held by Orbion Pharmaceuticals, was first approved by FDA on Jul 2, 2007, with 9 approved supplements and 0 published complete response letters.
Terbinafine tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing [potassium hydroxide (KOH) preparation, fungal culture, or nail biopsy] should be obtained to confirm the diagnosis of onychomycosis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 2, 2007 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Terbinafine HydrochlorideEQ 250MG BASE · tablet;oral | Terbinafine Hydrochloride | Rx |
| Sep 12, 2025 | Supplement 12Labeling · Standard review | Approved | None posted |
| Sep 12, 2025 | Supplement 10Labeling · Standard review | Approved | None posted |
| Sep 12, 2025 | Supplement 9Labeling · Standard review | Approved | None posted |
| Sep 24, 2015 | Supplement 8Labeling · Standard review | Approved | None posted |
| Sep 24, 2015 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jul 12, 2012 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 12, 2012 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 14, 2011 | Supplement 2Labeling | Approved | None posted |
| Dec 13, 2011 | Supplement 3Labeling | Approved | None posted |
| Jul 2, 2007 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters